Aquestive Therapeutics (AQST) Invested Capital (2017 - 2025)
Historic Invested Capital for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $2.2 million.
- Aquestive Therapeutics' Invested Capital rose 62809.52% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 62809.52%. This contributed to the annual value of -$15.2 million for FY2024, which is 7535.09% up from last year.
- As of Q3 2025, Aquestive Therapeutics' Invested Capital stood at $2.2 million, which was up 62809.52% from -$69.4 million recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' Invested Capital registered a high of $9.5 million during Q2 2024, and its lowest value of -$98.3 million during Q3 2023.
- Over the past 5 years, Aquestive Therapeutics' median Invested Capital value was -$61.5 million (recorded in 2023), while the average stood at -$54.1 million.
- The largest annual percentage gain for Aquestive Therapeutics' Invested Capital in the last 5 years was 62809.52% (2025), contrasted with its biggest fall of 82905.16% (2025).
- Quarter analysis of 5 years shows Aquestive Therapeutics' Invested Capital stood at -$80.1 million in 2021, then increased by 16.3% to -$67.1 million in 2022, then rose by 8.3% to -$61.5 million in 2023, then skyrocketed by 75.35% to -$15.2 million in 2024, then skyrocketed by 114.63% to $2.2 million in 2025.
- Its Invested Capital was $2.2 million in Q3 2025, compared to -$69.4 million in Q2 2025 and -$60.9 million in Q1 2025.